Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects

Study Identifier
S187.3.003
CT.gov Identifier
EudraCT Identifier
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Results Available

Scientific Result Summary
Available Language(s): English

Study Details

Medical Condition
  • Parkinson's Disease
  • Study Drug
  • Levodopa-carbidopa intestinal gel
  • Phase
    Phase 3
    Sex
    Female & Male
    Age
    30+ years

    Protocol Summary

    Long term safety and efficacy (12 months) of levodopa-carbidopa intestinal gel.

    Study Locations

    Location
    Status
    Location
    Site Reference ID/Investigator# 45869
    Birmingham, Alabama, United States, 35222
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 45834
    Fountain Valley, California, United States, 92708
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 45854
    Los Angeles, California, United States, 90033
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 45856
    Oceanside, California, United States, 92056
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 45859
    Washington D.C., District of Columbia, United States, 20007
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 45857
    Bradenton, Florida, United States, 34205
    Status
    Not applicable
    Showing {first} - {last} of {total} Results